CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Novo Nordisk

Liselotte Hyveled, Chief Patient Officer, Board member

Strengthening Patient Centricity In Drug Development: The New Evolution In Pharma

Liselotte Hyveled

Liselotte Hyveled

In recent years, the pharmaceutical industry has witnessed a significant shift towards pa-tient-centric drug development. This evolution is not just a trend but a fundamental change in how drugs are developed, tested and brought to market. Many pharma companies have claimed patient centricity for years, but what does patient centricity truly mean and why do we see a shift now and why is it so crucial for the future of pharma?


What is Patient Centricity?


Patient centricity refers to the practice of designing and developing drugs with the patient's needs, preferences and experiences at the core. This approach involves engaging patients throughout the drug development process, from initial research to clinical trials and post-market surveillance. The goal is to create treatments that are not only effective but also align with the patient's lifestyle and improve their overall quality of life.


The Importance of Patient Centricity


1. Improved Treatment Outcomes


When patients are involved in the development process, their insights can lead to more ef-fective and personalised treatments. For instance, understanding the daily challenges faced by people with diabetes can help in designing insulin delivery systems that are more con-venient and less intrusive.


2. Enhanced Patient Compliance


Drugs that are developed with patient input are more likely to be userfriendly, which can significantly improve adherence to treatment regimens. This is particularly important for chronic conditions where long-term medication is necessary.


Strengthening patient centricity in drug development is not just an evolution but a revolution in the pharmaceutical industry. By placing patients at the heart of the development process, companies are not only improving treatment outcomes but also enhancing the overall patient experience


3. Accelerated Drug Development


Engaging patients early in the development process can help identify potential issues before they become significant problems. This proactive approach can streamline clinical trials and reduce the time it takes to bring a new drug to market.


 4. Regulatory Support


Regulatory bodies like the FDA and EMA are increasingly emphasising the importance of patient-centric approaches. Several guidelines related to patient focused drug development have been issued in the past years. Hence, incorporating patient feedback can facilitate smoother regulatory approvals and ensure that new treatments meet the highest standards of safety and efficacy.


Pharma companies Commitment to Patient Centricity


Pharma is increasingly expanding their focus to include patient input through the value chain from early research to market. The company's approach involves:


Collaborative Research


Collaboration with academic institutions, biotech firms and technology companies to lever-age diverse expertise and accelerate drug development. For example, their partnership with tech companies can aim to use artificial intelligence and big data to enhance research and development efforts.


Innovative Clinical Trials


Many companies are focused on making clinical trials more accessible and less burdensome for participants. This may include using digital tools and remote monitoring to reduce the need for frequent clinic visits.


Holistic approaches


Drug development is not only about the drug. Many pharma companies seek to create a holistic treatment approach, looking at diagnostic, device, drug, digital and other solutions that may meet the patients challenges and unmet need for better treatment outcomes.


Patient Advocacy


Companies to an increasing degree engages with patient advocacy groups to understand the needs and preferences of the communities they serve. This ongoing dialogue helps shape the development of new treatments and ensures that patient voices are heard.


Conclusion


Strengthening patient centricity in drug development is not just an evolution but a revolution in the pharmaceutical industry. By placing patients at the heart of the development process, companies are not only improving treatment outcomes but also enhancing the overall patient experience. As this approach continues to gain momentum, it promises to transform the future of healthcare, making it more responsive, inclusive and effective.


By focusing on patient centricity, we are setting a new standard in the pharmaceutical in-dustry, one that prioritises the needs and well-being of patients above all else. This evolution is a testament to my company's commitment to driving change and improving lives.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://bioanalytical-services-europe.lifesciencesreview.com/cxoinsight/strengthening-patient-centricity-in-drug-development-the-new-evolution-in-pharma-nwid-2426.html